Redeye increases its fair value range following a closer look at the report. We were positively surprised by higher US CERAMENT G sales (ahead of any meaningful trauma indication contribution) and higher EBIT than we estimated. We make minor changes to our estimates on all time horizons and lower our WACC following a review of BONESUPPORT’s qualities.